Table 2.

IL-17A and the effect of weight gain (increased BMI) on drug efficacy.

IL-17A Inhibitors	Structure and Mechanism	Effect on BMI/Weight Gain	Influence of BMI on Drug Efficacy	Commentary
Secukinumab	recombinant fully human IgG1/kappa monoclonal antibody	Constant BMI levels; no weight gain [35,38]	Similar drug efficacy regardless of BMI values [35]; one study revealed that individuals <90kg had higher response rates [48]	Could be a better alternative for obese patients; Lack of sufficient data requires for extensive research to draw definitive conclusions
Ixekizumab	complete monoclonal antibody of the subclass IgG4	No significant weight gain [36,38]; Lack of sufficient data	Similar drug efficacy regardless of BMI values [37]	Could be a better alternative for obese patients; Lack of sufficient data requires for extensive research to draw definitive conclusions